These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38510992)

  • 1. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis.
    Mosquera-Orgueira A; Arellano-Rodrigo E; Garrote M; Martín I; Pérez-Encinas M; Gómez-Casares MT; Hernández-Sánchez A; Ferrer-Marín F; Mora E; Velez P; Ayala R; Angona A; Heras NL; Magro E; Pérez-Míguez C; Crucitti D; Mata-Vázquez MI; Fox ML; González de Villambrosía S; Ramírez MJ; García A; García-Gutiérrez V; Cáceres A; Durán MA; Senín MA; Raya JM; González JA; Cuevas B; Xicoy B; Nangalia J; Hernández-Rivas JM; Bellosillo B; Álvarez-Larrán A; Hernández-Boluda JC;
    Hemasphere; 2024 Mar; 8(3):e60. PubMed ID: 38510992
    [No Abstract]   [Full Text] [Related]  

  • 2. AIPSS-MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib.
    Duminuco A; Mosquera-Orgueira A; Nardo A; Di Raimondo F; Palumbo GA
    Cancer Rep (Hoboken); 2023 Oct; 6(10):e1881. PubMed ID: 37553891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis.
    Mosquera-Orgueira A; Pérez-Encinas M; Hernández-Sánchez A; González-Martínez T; Arellano-Rodrigo E; Martínez-Elicegui J; Villaverde-Ramiro Á; Raya JM; Ayala R; Ferrer-Marín F; Fox ML; Velez P; Mora E; Xicoy B; Mata-Vázquez MI; García-Fortes M; Angona A; Cuevas B; Senín MA; Ramírez-Payer A; Ramírez MJ; Pérez-López R; González de Villambrosía S; Martínez-Valverde C; Gómez-Casares MT; García-Hernández C; Gasior M; Bellosillo B; Steegmann JL; Álvarez-Larrán A; Hernández-Rivas JM; Hernández-Boluda JC
    Hemasphere; 2023 Jan; 7(1):e818. PubMed ID: 36570691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis of prognostic factors in Chinese patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis].
    Chen M; Xu ZF; Xu JQ; Li B; Zhang PH; Qin TJ; Zhang Y; Wang JY; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):876-880. PubMed ID: 27801320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates.
    Kuykendall AT; Mo Q; Sallman DA; Ali NA; Chan O; Yun S; Sweet KL; Padron E; Lancet JE; Komrokji RS
    Cancer; 2022 Oct; 128(19):3495-3501. PubMed ID: 35942592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
    Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
    Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
    Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
    Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis.
    Gianelli U; Vener C; Bossi A; Cortinovis I; Iurlo A; Fracchiolla NS; Savi F; Moro A; Grifoni F; De Philippis C; Radice T; Bosari S; Lambertenghi Deliliers G; Cortelezzi A
    Mod Pathol; 2012 Sep; 25(9):1193-202. PubMed ID: 22627739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
    Masarova L; Verstovsek S
    Clin Adv Hematol Oncol; 2019 May; 17(5):299-307. PubMed ID: 31188809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis.
    Gill H; Leung AY; Chan CC; Lau JS; Chan C; Yip SF; Liu H; Kho B; Mak V; Lee HK; Lin SY; Lau CK; Kwong YL
    Hematology; 2016 Jan; 21(1):10-8. PubMed ID: 26292161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive predictors of skill acquisition on social problem solving in patients with schizophrenia.
    Uçok A; Cakir S; Duman ZC; Dişcigil A; Kandemir P; Atli H
    Eur Arch Psychiatry Clin Neurosci; 2006 Sep; 256(6):388-94. PubMed ID: 16783500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
    Shide K; Takenaka K; Kitanaka A; Numata A; Kameda T; Yamauchi T; Inagaki A; Mizuno S; Takami A; Ito S; Hagihara M; Usuki K; Maekawa T; Sunami K; Ueda Y; Tsutsui M; Ando M; Komatsu N; Ozawa K; Kurokawa M; Arai S; Mitani K; Akashi K; Shimoda K
    Ann Hematol; 2024 Jan; 103(1):97-103. PubMed ID: 37946031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.
    Verma T; Papadantonakis N; Peker Barclift D; Zhang L
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of clinical features and prognosis of primary myelodysplastic syndromes with myelofibrosis patients].
    Su T; Zhang PH; Xu ZF; Chen HS; Qin TJ; Zhang Y; Zhang HL; Fan LW; Pan LJ; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):378-82. PubMed ID: 22781796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70-A Retrospective Study.
    Messerich NM; Uda NR; Volken T; Cogliatti S; Lehmann T; Holbro A; Benz R; Graf L; Gupta V; Jochum W; Demmer I; Rao TN; Silzle T
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.
    Mead AJ; Butt NM; Nagi W; Whiteway A; Kirkpatrick S; Rinaldi C; Roughley C; Ackroyd S; Ewing J; Neelakantan P; Garg M; Tucker D; Murphy J; Patel H; Bains R; Chiu G; Hickey J; Harrison C; Somervaille TCP
    Ther Adv Hematol; 2022; 13():20406207221084487. PubMed ID: 35371428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
    Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
    Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fibrosis-driving cells in patients with primary myelofibrosis and myelodysplastic syndromes with myelofibrosis].
    Cai YN; Zhang PH; Fang LH; Liu JQ; Li B; Xu ZF; Qin TJ; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Dec; 41(12):1002-1007. PubMed ID: 33445847
    [No Abstract]   [Full Text] [Related]  

  • 19. Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
    Palandri F; Breccia M; Mazzoni C; Auteri G; Elli EM; Trawinska MM; Polverelli N; Tiribelli M; Benevolo G; Iurlo A; Tieghi A; Heidel FH; Caocci G; Beggiato E; Binotto G; Cavazzini F; Miglino M; Bosi C; Crugnola M; Bocchia M; Martino B; Pugliese N; Biondo M; Venturi M; Scaffidi L; Isidori A; Cattaneo D; Krampera M; Pane F; Cilloni D; Semenzato G; Lemoli RM; Cuneo A; Abruzzese E; Bartoletti D; Paglia S; Vianelli N; Cavo M; Bonifacio M; Palumbo GA
    Cancer; 2023 Jun; 129(11):1704-1713. PubMed ID: 36932983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcription factor 3 is dysregulated in megakaryocytes in myelofibrosis.
    Collinson RJ; Wilson L; Boey D; Ng ZY; Mirzai B; Chuah HS; Howman R; Grove CS; Malherbe JAJ; Leahy MF; Linden MD; Fuller KA; Erber WN; Guo BB
    Platelets; 2024 Dec; 35(1):2304173. PubMed ID: 38303515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.